The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up

No abstract is available for this paper.

• Publication year

  2012

• Venue

  BJU International

• Publication date

  2012-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-410X.2011.10422.xPMID 21777360PMCID PMC3204323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

  2010cited by this paper
• Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.

  2010cited by this paper
• Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

  2008cited by this paper
• The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.

  2008cited by this paper
• Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.

  2008cited by this paper
• Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.

  2007cited by this paper
• Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.

  2007cited by this paper
• Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

  2007cited by this paper
• Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.

  2007cited by this paper
• Rising PSA in nonmetastatic prostate cancer.

  2007cited by this paper
• Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer

  2006cited by this paper
• Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

  2006cited by this paper
• Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline.

  2005cited by this paper
• Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

  2005cited by this paper
• Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy

  2005cited by this paper
• Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.

  2004cited by this paper
• Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

  2004cited by this paper
• Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.

  2004cited by this paper
• Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database.

  2004cited by this paper
• The Statistical Analysis of Failure Time Data

  2003cited by this paper
• Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

  2003cited by this paper
• Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer.

  2002cited by this paper
• Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.

  2002cited by this paper
• Statistical problems with ‘optimal’ thresholds in studies of new prognostic factors in urology

  2000cited by this paper
• Natural history of progression after PSA elevation following radical prostatectomy.

  1999cited by this paper
• Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

  1998cited by this paper
• Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.

  1997cited by this paper
• Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.

  1997cited by this paper
• Linear regressive analysis using prostate‐specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

  1993cited by this paper
• Cancer statistics

  1989cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper

• Metastasis-Free Survival in Patients with Biochemical Recurrence After Robot-Assisted Radical Prostatectomy: A Multicenter, Retrospective Cohort Study in Japan (MSUG94 Group)

  2026influential citation
• Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).

  2026cites this paper
• What's in a name? Why differentiation between biochemical recurrence and metastatic prostate cancer matters.

  2025cites this paper
• Drug treatment options of high-risk biochemically recurrent prostate cancer based on efficacy and safety: a systematic review and Bayesian network analysis

  2025cites this paper
• Preoperative serum inflammatory markers in the prognostic assessment of hepatocellular carcinoma resection in stages I/II

  2025cites this paper
• Integration of Primary Care Into the Follow‐Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region

  2025cites this paper
• Serum peptide biomarkers by MALDI-TOF MS coupled with machine learning for diagnosis and classification of hepato-pancreato-biliary cancers

  2025cites this paper
• Identification of serum peptide biomarkers for cholangiocarcinoma diagnosis and staging via MALDI-TOF MS and LC-MS/MS

  2025cites this paper
• Human bone marrow adipocytes drive prostate cancer bone metastasis progression via lipid-mediated induction of Angiopoietin-like 4

  2025cites this paper
• Discovery of novel serum peptide biomarkers for cholangiocarcinoma recurrence through MALDI-TOF MS and LC–MS/MS peptidome analysis

  2025cites this paper
• Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer: Current and emerging strategies.

  2025cites this paper
• Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study

  2025cites this paper
• National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

  2025cites this paper
• How to tailor the radiotherapy after radical prostatectomy in the modern era of molecular imaging, genomic testing, and technology development?

  2025cites this paper
• Prostate cancer treatment recommendation study based on machine learning and SHAP interpreter

  2024cites this paper
• snRNAs from Radical Prostatectomy Specimens Have the Potential to Serve as Prognostic Factors for Clinical Recurrence after Biochemical Recurrence in Patients with High-Risk Prostate Cancer

  2024cites this paper
• Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment

  2024cites this paper
• PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

  2024cites this paper
• Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life

  2024cites this paper
• Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up

  2024cites this paper
• Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients

  2024cites this paper
• Prognostic factors for non‑metastatic castration‑resistant prostate cancer treated with androgen receptor signaling inhibitors

  2024cites this paper
• When You Get to the Fork in the Road, Take It: The Challenges in Managing Patients With Advanced Prostate Cancer.

  2024cites this paper
• Association between mpMRI detected tumor apparent diffusion coefficient and 5-year biochemical recurrence risk after radical prostatectomy

  2024cites this paper
• Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

  2024cites this paper
• Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer

  2024cites this paper
• Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment

  2024cites this paper
• Trifecta Outcomes After Use of 3-Dimensional Digital Models for Planning of Robotic Prostatectomy

  2024cites this paper
• Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

  2023cites this paper
• A Novel Four Mitochondrial Respiration-Related Signature for Predicting Biochemical Recurrence of Prostate Cancer

  2023cites this paper
• Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

  2023influential citation
• Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.

  2023cites this paper
• Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification

  2023cites this paper
• Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer.

  2023cites this paper
• Quality by design fostered fabrication of cabazitaxel loaded pH-responsive Improved nanotherapeutics against prostate cancer.

  2023cites this paper
• An anoikis-related gene signature for prediction of the prognosis in prostate cancer

  2023cites this paper
• Intermittent Androgen Deprivation for Biochemically Recurrent Prostate Cancer: First Do No Harm.

  2023cites this paper
• Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number

  2023cites this paper
• Poorly Controlled Diabetes Mellitus Increases the Risk of Deaths and Castration-Resistance in Locally Advanced Prostate Cancer Patients

  2023cites this paper
• The natural history of a delayed detectable PSA after radical prostatectomy

  2023cites this paper
• The Development of a Gleason Score-Related Gene Signature for Predicting the Prognosis of Prostate Cancer

  2022cites this paper
• Identification and validation of a lipid metabolism gene signature for predicting biochemical recurrence of prostate cancer after radical prostatectomy

  2022cites this paper
• Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential

  2022cites this paper
• Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort study

  2022cites this paper
• Direct bone marrow injection of human bone marrow-derived stromal cells into mouse femurs results in greater prostate cancer PC-3 cell proliferation, but not specifically proliferation within the injected femurs

  2022cites this paper
• Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry

  2022cites this paper
• Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative.

  2022cites this paper
• With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.

  2022cites this paper
• Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: A systematic review and meta-analysis

  2022cites this paper
• Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives

  2022influential citation
• Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.

  2022cites this paper
• Prostate Surface Distension and Tumor Texture Descriptors From Pre-Treatment MRI Are Associated With Biochemical Recurrence Following Radical Prostatectomy: Preliminary Findings

  2022cites this paper
• Biochemical recurrence after radical prostatectomy – a large, comprehensive, population-based study with long follow-up

  2022cites this paper
• A Ferroptosis-Related Gene Prognostic Index Associated With Biochemical Recurrence and Radiation Resistance for Patients With Prostate Cancer Undergoing Radical Radiotherapy

  2022cites this paper
• The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer

  2022cites this paper
• Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer

  2022cites this paper
• High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure.

  2021cites this paper
• Effect of Salvage Radiotherapy and Endocrine Therapy on Patients with Biochemical Recurrence After Prostate Cancer Operation— a Meta‑Analysis

  2021cites this paper
• Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?

  2021cites this paper
• A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries

  2021cites this paper
• Impact of Dutasteride on PSA Kinetics and Time to Progression in Men with PSA-only Recurrent Prostate Cancer

  2021cites this paper
• Evaluation of circulating β2-microglobulin as a prognostic factor for biochemical recurrence after radical prostatectomy

  2021cites this paper
• Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.

  2021cites this paper
• Metastatic prostate adenocarcinoma and high-grade appendiceal mucinous neoplasm mimicking acute appendicitis in a post-radiation therapy patient

  2021cites this paper
• A Glycolysis-Related Five-Gene Signature Predicts Biochemical Recurrence-Free Survival in Patients With Prostate Adenocarcinoma

  2021cites this paper
• Magnetic Resonance Imaging‒Targeted Biopsy of the Prostate

  2021cites this paper
• 68Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy

  2021cites this paper
• Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement.

  2021cites this paper
• Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy.

  2021cites this paper
• Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade

  2021cites this paper
• MiRNAs and radical prostatectomy: Current data, bioinformatic analysis and utility as predictors of tumour relapse

  2021cites this paper
• Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study

  2021cites this paper
• Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?

  2021cites this paper
• Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

  2021cites this paper
• Tissue N-linked glycosylation as potential prognostic biomarker for biochemical recurrence-free survival

  2021cites this paper
• Salvage therapy for prostate cancer after radical prostatectomy

  2021cites this paper
• 68 Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy

  2021cites this paper
• Impact of Dutasteride on PSA Kinetics and Time to Progression in Men with PSA-only Recurrent Prostate Cancer

  2021cites this paper
• Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

  2021cites this paper
• Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients

  2020cites this paper
• Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence.

  2020cites this paper
• Early salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: Its impact and optimal candidate

  2020cites this paper
• Magnetic Resonance Imaging‒Targeted Biopsy of the Prostate

  2020cites this paper
• Economic evaluation of robot-assisted radical prostatectomy compared to open radical prostatectomy for prostate cancer treatment in Ontario, Canada.

  2020cites this paper
• Gene Expression-Based Immune Cell Infiltration Analyses of Prostate Cancer and Their Associations with Survival Outcome

  2020cites this paper
• A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

  2020cites this paper
• Detectable Prostate-specific antigen value between 0.01 and 0.1 ng/ml following robotic-assisted radical prostatectomy (RARP): does it correlate with future biochemical recurrence?

  2020cites this paper
• Prostate Cancer in Latin America: Challenges and Recommendations

  2020cites this paper
• A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients.

  2020cites this paper
• Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence

  2020cites this paper
• Phase 2 Trial of Monoamine Oxidase Inhibitor Phenelzine in Biochemical Recurrent Prostate Cancer

  2020cites this paper
• Genomic and phenotypic heterogeneity in prostate cancer

  2020cites this paper
• Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis

  2020cites this paper
• Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?

  2020cites this paper
• BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK.

  2020cites this paper
• Patterns of Lymph Node Failure in Patients With Recurrent Prostate Cancer Postradical Prostatectomy and Implications for Salvage Therapies

  2020cites this paper
• In Vitro Study of Calcium Microsecond Electroporation of Prostate Adenocarcinoma Cells

  2020cites this paper
• Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study

  2020cites this paper
• Prostate Cancer, Update of its Diagnosis and Treatment, with Special Emphasis on its Management in Argentina

  2020cites this paper
• Comparison of The Functional and Oncological Outcomes of the Sub-trigonal Versus Conventional Robotic Radical Prostatectomy for Prostate Cancer

  2020cites this paper